Lilly to appeal FDA's approvable letter for Arxxant

Share this article:
Eli Lilly says it will appeal the FDA's decision to issue an "approvable letter" that requests an additional efficacy study for Arxxant, its new drug for moderate to severe nonproliferative diabetic retinopathy. Its appeal will be based on unmet medical need for the drug, demonstrated efficacy and Arxxant's "robust safety profile."
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.